Home
YMAB
YMAB News

Latest Y-mAbs Therapeutics Inc. (YMAB) News on November 17, 2024

GuruFocus.com

8 days ago

Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

Zacks

9 days ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire

9 days ago

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings

GuruFocus.com

10 days ago

What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

12 days ago

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

GlobeNewswire

13 days ago

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know

Zacks

16 days ago

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

GlobeNewswire

23 days ago

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

GuruFocus.com

a month ago

Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ...

Y-mAbs to Participate in Upcoming Investor Conferences in October

GlobeNewswire

2 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in October

While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate

Simply Wall St.

2 months ago

While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate

MT Newswires

2 months ago

Y-mAbs Therapeutics Signs Lease Deal for New Jersey Property

MT Newswires

2 months ago

Y-mAbs Therapeutics' Neuroblastoma Drug Shows Consistent Disease Control in Clinical Study

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

GlobeNewswire

2 months ago

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Y-mAbs to Participate in Upcoming Investor Conferences in September

GlobeNewswire

2 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in September

MT Newswires

3 months ago

Cantor Fitzgerald Initiates Coverage on Y-mAbs Therapeutics With Overweight Rating, $20 Price Target

Why Y-mAbs Therapeutics Stock Got Mashed on Monday

Motley Fool

3 months ago

Why Y-mAbs Therapeutics Stock Got Mashed on Monday

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates

Zacks

3 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire

3 months ago

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top Holdings Now?

Insider Monkey

3 months ago

Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top Holdings Now?

Y-mAbs to Participate in Upcoming Investor Conferences in August

GlobeNewswire

3 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in August

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

GlobeNewswire

3 months ago

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Simply Wall St.

4 months ago

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

MT Newswires

5 months ago

Y-mAbs Therapeutics Appoints Peter Pfreundschuh as CFO

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

GlobeNewswire

5 months ago

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

MT Newswires

5 months ago

Truist Initiates Y-mAbs Therapeutics at Buy With $21 Price Target, Calls Radioimmunotherapy Platform 'Undervalued'

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

5 months ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

5 months ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

5 months ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

5 months ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

5 months ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

5 months ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

5 months ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

5 months ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional investors' interest

Simply Wall St.

5 months ago

With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional investors' interest

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

GlobeNewswire

5 months ago

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

GlobeNewswire

5 months ago

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

GlobeNewswire

6 months ago

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

GlobeNewswire

6 months ago

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript

Insider Monkey

6 months ago

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript

GuruFocus.com

6 months ago

Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

Thomson Reuters StreetEvents

6 months ago

Q1 2024 Y-mAbs Therapeutics Inc Earnings Call

Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates

GuruFocus.com

6 months ago

Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates

Zacks

6 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire

6 months ago

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

GlobeNewswire

7 months ago

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

Y-mAbs to Present at 2024 ASCO Annual Meeting

GlobeNewswire

7 months ago

Y-mAbs to Present at 2024 ASCO Annual Meeting

Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%

Simply Wall St.

7 months ago

Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%

Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet

Zacks

8 months ago

Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet

YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?

Zacks

8 months ago

YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

GlobeNewswire

8 months ago

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?

Zacks

8 months ago

Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?

Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice

Zacks

8 months ago

Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

GlobeNewswire

8 months ago

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Y-mAbs Therapeutics Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Y-mAbs Therapeutics Full Year 2023 Earnings: Beats Expectations

Thomson Reuters StreetEvents

9 months ago

Q4 2023 Y-mAbs Therapeutics Inc Earnings Call

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates

Zacks

9 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates

GuruFocus.com

9 months ago

Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

GlobeNewswire

9 months ago

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline

Zacks

9 months ago

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline

CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?

Zacks

9 months ago

CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

GlobeNewswire

9 months ago

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?

Zacks

9 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Whirlpool Corp Earnings Call

Here's Why We're Not At All Concerned With Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation

Simply Wall St.

10 months ago

Here's Why We're Not At All Concerned With Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation

Invesco Closed-End Funds Declare Dividends

PR Newswire

10 months ago

Invesco Closed-End Funds Declare Dividends

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

GlobeNewswire

10 months ago

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

i-80 Gold Reports High-Grade Drill Results from the FAD Deposit at Ruby Hill

CNW Group

10 months ago

i-80 Gold Reports High-Grade Drill Results from the FAD Deposit at Ruby Hill

CENTERSPACE ANNOUNCES 2023 DIVIDEND ALLOCATIONS

PR Newswire

10 months ago

CENTERSPACE ANNOUNCES 2023 DIVIDEND ALLOCATIONS

TrustCo’s Total Loans Surpass $5 Billion - Reach All-Time High; Nonperforming Assets to Total Assets at 0.29%, Lowest in 17 Years

GlobeNewswire

10 months ago

TrustCo’s Total Loans Surpass $5 Billion - Reach All-Time High; Nonperforming Assets to Total Assets at 0.29%, Lowest in 17 Years

The Return Trends At DHT Holdings (NYSE:DHT) Look Promising

Simply Wall St.

10 months ago

The Return Trends At DHT Holdings (NYSE:DHT) Look Promising

AdvanSix Provides Update on Plant Production Rates

Business Wire

10 months ago

AdvanSix Provides Update on Plant Production Rates

CENTERSPACE ANNOUNCES FOURTH QUARTER 2023 EARNINGS RELEASE DATE

PR Newswire

10 months ago

CENTERSPACE ANNOUNCES FOURTH QUARTER 2023 EARNINGS RELEASE DATE

Vital Farms Inc President and CEO Russell Diez-Canseco Sells 27,560 Shares

GuruFocus.com

10 months ago

Vital Farms Inc President and CEO Russell Diez-Canseco Sells 27,560 Shares

i-80 Gold Announces High-Grade Results from Hilltop Drilling at Ruby Hill

PR Newswire

10 months ago

i-80 Gold Announces High-Grade Results from Hilltop Drilling at Ruby Hill

Runway Growth Finance Corp. Announces Date for Fourth Quarter and Full Year 2023 Financial Results and Conference Call

GlobeNewswire

10 months ago

Runway Growth Finance Corp. Announces Date for Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Procaps Group – Notice to Shareholders

Business Wire

10 months ago

Procaps Group – Notice to Shareholders

AdvanSix to Release Fourth Quarter Financial Results and Hold Investor Conference Call on February 16

Business Wire

10 months ago

AdvanSix to Release Fourth Quarter Financial Results and Hold Investor Conference Call on February 16

Centrus Energy Corp. (LEU) Soars 7.9%: Is Further Upside Left in the Stock?

Zacks

10 months ago

Centrus Energy Corp. (LEU) Soars 7.9%: Is Further Upside Left in the Stock?

Reuters

10 months ago

UPDATE 1-US seeks to jump-start production of higher-energy uranium now made in Russia

Reuters

10 months ago

US seeks to jump-start production of higher-energy uranium now made in Russia

Universal Stainless (USAP) Surges 76% in 3 Months: Here's Why

Zacks

10 months ago

Universal Stainless (USAP) Surges 76% in 3 Months: Here's Why

i-80 Provides 2023 Summary & 2024 Plans - Highlighting Numerous Achievements & Catalysts

PR Newswire

10 months ago

i-80 Provides 2023 Summary & 2024 Plans - Highlighting Numerous Achievements & Catalysts

Investors in Universal Logistics Holdings (NASDAQ:ULH) have seen respectable returns of 50% over the past five years

Simply Wall St.

10 months ago

Investors in Universal Logistics Holdings (NASDAQ:ULH) have seen respectable returns of 50% over the past five years

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

GlobeNewswire

10 months ago

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

Why LifeMD's CEO isn't concerned about Eli Lilly's DTC site

Yahoo Finance Video

10 months ago

Why LifeMD's CEO isn't concerned about Eli Lilly's DTC site

New Found Increases Queensway Drill Program to 650,000 Metres, Seismic Interpretation to Guide 2024 Targeting

Business Wire

10 months ago

New Found Increases Queensway Drill Program to 650,000 Metres, Seismic Interpretation to Guide 2024 Targeting

TDCX Inc. Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Remaining Outstanding Class A Ordinary Shares of the Company

Business Wire

10 months ago

TDCX Inc. Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Remaining Outstanding Class A Ordinary Shares of the Company

Pennant and John Muir Health Enter into a Home Health Joint Venture in the Bay Area, California

GlobeNewswire

10 months ago

Pennant and John Muir Health Enter into a Home Health Joint Venture in the Bay Area, California

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Business Wire

10 months ago

Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is definitely on the radar of institutional investors who own 40% of the company

Simply Wall St.

10 months ago

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is definitely on the radar of institutional investors who own 40% of the company

Procaps Group Reports Third Quarter 2023 Results

Business Wire

a year ago

Procaps Group Reports Third Quarter 2023 Results

Statement from the Board of Directors of Procaps Group

Business Wire

a year ago

Statement from the Board of Directors of Procaps Group

Business Wire

a year ago

Paragon 28 to Present at the 42nd Annual J.P. Morgan Healthcare Conference

FuelCell Energy Stock Falls as Revenue Drops 43%

Barrons.com

a year ago

FuelCell Energy Stock Falls as Revenue Drops 43%

Here's What We Like About Hackett Group's (NASDAQ:HCKT) Upcoming Dividend

Simply Wall St.

a year ago

Here's What We Like About Hackett Group's (NASDAQ:HCKT) Upcoming Dividend

Best Dividend Stocks Paying Yields Over the Rate of Inflation in December 2023

Investopedia

a year ago

Best Dividend Stocks Paying Yields Over the Rate of Inflation in December 2023

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

GlobeNewswire

a year ago

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

Share on Social Networks: